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Abstract Beta-2 glycoprotein I (h2GPI) is the principal target of autoantibodies in
the antiphospholipid syndrome (APS). It is abundant in human plasma and shares high
homology between different mammalian species. Although the exact physiological
function of h2GPI has not been fully elucidated, several interactions have been
described with other proteins and with negatively charged surfaces, such as anionic
phospholipids, dextran and heparin. h2GPI is involved in the coagulation pathway,
exerting both procoagulant and anticoagulant activities. Plasma from h2GPI-
deficient mice exhibits impaired thrombin generation in vitro. Recently, it has been
demonstrated that h2GPI binds factor (F) XI in vitro at concentrations lower than
those of the protein in human plasma, and this binding inhibits FXI activation to FXIa
by thrombin and FXIIa. Proteolytic cleavage of the fifth domain of h2GPI abolishes its
inhibition of FXI activation and results in reduced ability of the cleaved h2GPI to bind
phospholipids. It retains its ability to bind FXI. In vivo activation of FXI by thrombin is
thought to be an important mechanism by which coagulation is accelerated via
components of the contact activation pathway. Thus h2GPI may attenuate the
contact activation pathway by inhibiting activation of FXI by thrombin. Moreover,
because h2GPI is the dominant autoantigen in patients with APS, dysregulation of
this pathway by autoantibodies may be an important mechanism for thrombosis in
patients with APS.
D 2004 Published by Elsevier Ltd.
Introduction
Beta-2 glycoprotein I (h2GPI) is the major antigen
bound by antibodies demonstrable in the antiphos-
pholipid syndrome (APS) [1]. h2GPI was first
described in the early 1960s as a component of
the beta-globulin fraction of human serum [2]. This
molecule was classified as an apolipoprotein, and it
was initially termed apolipoprotein H. Thirty years
following its discovery, clear evidence emerged
that h2GPI is the major antigenic target for
antiphospholipid antibodies (aPLAb) circulating in
the plasma of APS patients [3]. This breakthrough
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generated great interest in h2GPI, and its role in
the pathogenesis of autoantibodies underlying APS.
The role of this protein in the coagulation system
both in healthy people and patients with APS is
being increasingly elucidated. For example, an
anticoagulant effect of this protein has been
demonstrated in in vitro systems [4]. Moreover,
h2GPI has varied and interesting interactions with
several other proteins and with negatively charged
surfaces, such as heparin, DNA, dextran and anionic
phospholipid, independent of any involvement with
autoantibodies [5,6]. The report that follows will
discuss the main properties of h2GPI, summarizing
existing evidence and theories on the physiological
role of this protein, as well as its involvement in the
pathogenesis of the APS.
B2GPI—general considerations
h2GPI is a single-chain protein with 326 amino
acids, containing four N-linked glycosylation sites.
Its average molecular weight measured by reduced
SDS-PAGE is 54.2 kDa. The oligosaccharides in h2GPI
are highly heterogenous in structure. Despite the
fact that enzymatic deglycosylation of h2GPI seems
to modify its secondary structure, alterations in
glycosylation in recombinant human h2GPI do not
appear to affect cardiolipin binding nor the binding
of h2GPI dependent anticardiolipin antibodies [7].
The gene encoding h2GPI maps to chromosome
17q23-24, and its promoter has been characterized
recently [8]. h2GPI is highly conserved among
mammals. Human, bovine, canine and mouse
proteins all have five domains with 60—80% amino
acid sequence homology, domain V being the most
conserved [9,10].
Molecular structure of B2GPI
h2GPI consists of five repeating sequences, also
known as short consensus repeats (SCR; Fig. 1).
Thus, h2GPI belongs to the complement control
protein (CCP) superfamily, which also includes
molecules like complement receptor 1 and 2, C4b
binding protein, complement FH, clotting FXIII
(subunit-b), IL2 receptor and haptoglobin 2. The
first four SCRs have 60 amino acid residues,
including four cysteines each. Disulphide bridges
join the first to the third and the second to the
fourth cysteines to form a blooped-backQ structure,
known also as sushi domains [9]. Domains III and IV
have three and one n-linked glycosylation sites,
respectively [11].
The fifth domain contains a conserved positively
charged (multiple lysine) region between cysteines
281 and 288 that is critical for phospholipid binding
[12]. Many of the positively charged side chains are
located in a particular surface region of domain V,
consisting of three loops (Fig. 1A). Site-directed
mutagenesis, either reducing the net positive
charge of the central loop in this region (lysine
residues within positions 284—287 of the h2GPI
molecule) or disrupting the position of this loop (by
mutating the flanking cysteines) inhibits the bind-
ing of h2GPI to negatively charged phospholipids
[12]. In addition, the fifth domain has an extra 20
amino acid tail, terminating in a cysteine, that can
form a disulphide link with an extra cysteine found
midway between the standard second and third
cysteine residue positions [9]. This 20-residue tail-
loop (amino acids 307—326) is conserved between
human, bovine and canine species, differing only in
Figure 1 (A) A schematic representation of the h2GPI
structure at the domain level. The putative binding site
for anionic phospholipid surface on the fifth domain is
illustrated, so are the proposed glycosylation sites on
domains III and IV (three and one glycosylation sites,
respectively). Domain V also carries the lysine rich
positively charged region, as well as the hydrophobic
mobile insertion loop. Modified and reproduced with
permission from Bouma et al. [11]. (B) The crystal
structure of h2GPI (left) is shown in comparison with
the atomic model with complete carbohydrate chains and
transformed to the best fit to the experimental data
(right). For details see Ref. [18]. Reproduced with
permission from Hammel et al. [18].
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one residue in the rat and in two residues in the
mouse [13]. Much of this tail is highly mobile and
projects from the main surface of the fifth domain.
Cleavage by both plasmin and (less effectively) FXa
has been demonstrated to occur at this region
(Lys317—Thr318; [14,15]). This cleavage affects the
position of the lysine-rich region. Heparin can bind
to this lysine-rich region within the fifth domain of
h2GPI [6]. Moreover, heparin at therapeutic con-
centrations is able to enhance the plasmin-medi-
ated cleavage of the C-terminal region of h2GPI [6].
The lysine residues in the region Cys281—Cys288 on
the fifth domain are involved in binding of h2GPI to
FXI (Shi et al. unpublished data). Plasmin-mediated
cleavage of domain V abolishes the inhibitory action
of h2GPI on FXI activation, although cleaved h2GPI
is able to bind FXI [16]. Finally, polymorphisms of
domain V have been described, which affect
phospholipid binding, either by disrupting the
disulphide bridge forming the terminal tail or by
directly impairing binding to anionic phospholipids
[5].
In addition to the phospholipid binding region in
domain V, a secondary interaction between domain
I and phospholipid has also been suggested, which—
in contrast with domain V binding—occurs only at
low ionic strengths [17]. Whether this low-ionic-
strength interaction is of relevance physiologically
is still unclear. Thus, h2GPI binding to anionic
phospholipids could result either from the com-
bined interaction of the lysine-rich region with the
hydrophobic loop or from a two step process
involving domains V and I.
In summary, the structure of h2GPI suggests a
lipid membrane insertion area on the fifth domain,
two domains (III and IV) protected from proteolysis
by glycosylation and two further domains (I and II)
projecting away from the lipid surface into the
extracellular space, thus able to interact with
other proteins and/or antibodies (Fig. 1). Both
hydrophobic and electrostatic interactions appear
necessary for h2GPI and anionic phospholipids to
bind h2GPI does not bind to nonpolar phospholipids
such as phosphatidylcholine, suggesting that the
hydrophobic loop is insufficient alone. Cleavage of
the hydrophobic loop makes only a small difference
to heparin binding [6], suggesting that with hep-
arin, the electrostatic interactions are relatively
more important.
Evidence exists that the structure of h2GPI in
solution may be different from the crystal struc-
ture, the former being less elongated and more
bulky [18]. Differences in the overall shape
between crystal and solution structure are attrib-
uted to the carbohydrate units and to the flexibility
of the CCP domains (Fig. 1B and C). It has been
proposed that transitions between conformational
states directly correlate with the functional prop-
erties of the protein because the solution structure
shows less immunological activity [19]. The inter-
action of h2GPI with anionic phospholipids, plastic
microtitre plates or cellular receptors may reor-
ientate the CCP domains and increase the density
and/or induce exposure of neoepitopes [20]
required for antibody binding.
B2GPI in plasma
h2GPI is produced in the liver and the placenta
[9]. The mean serum level of h2GPI is about 200
mg/l, which makes h2GPI one of the most
abundant proteins in human serum, second only
to fibrinogen, among the plasma proteins involved
in clotting. Nucleotide polymorphisms of the
h2GPI gene result in varying protein levels
between individuals from different races, suggest-
ing an autosomal codominant allelic state with
normal and deficient alleles [21]. The heterozy-
gous state does not appear to be thrombophilic,
and, interestingly, individuals without detectable
h2GPI have been identified who appear clinically
well [22].
h2GPI circulates in plasma mainly free, but
also in lipid-bound form. The plasma level of
h2GPI may be increased in chronic infections. In
acute infections, it behaves as a negative acute
phase reactant, decreasing with albumin. It is
also decreased in the clinical setting of dissemi-
nated intravascular coagulation which suggests
the consumption of this molecule [4]. The level
of h2GPI is positively correlated with smoking,
male gender, increasing age and hyperlipidaemia
[23].
h2GPI binds to anionic or zwitterionic phospho-
lipids without the need for calcium ions. Binding
is achieved through the interactions of the lysine-
rich region and the mobile hydrophobic loop in
domain V of the protein [14]. Although the exact
physiological function of h2GPI in normal individ-
uals is still unknown, it is believed that, under
physiologic conditions, the protein exerts an
anticoagulant effect by displacing various coagu-
lation proteins from anionic phospholipid sites
[1].
h2GPI does not seem to bind to native LDL, and
most plasma h2GPI is independent of lipoproteins.
Nevertheless, oxidative modification of LDL results
in the interaction with h2GPI and the binding of
aPLAb, leading to the uptake of ox-LDL particles by
macrophages [20]. Not surprisingly, therefore,
Beta 2 glycoprotein I—function in health and disease 337
h2GPI is present in atherosclerotic plaques [24].
Furthermore, macrophage phagocytosis is induced
by h2GPI binding to anionic phospholipids, even in
the absence of aPLAb [17], which suggests that
h2GPI functions as a marker for apoptotic or
necrotic cells.
B2GPI in the coagulation cascade
h2GPI has been shown to interact with a number of
steps of the coagulation and fibrinolytic pathways
(Fig. 2). The addition of anti-h2GPI antibodies to
normal human plasma has been shown to cause
prolongation in thrombin generation [25]. More
recently, mice lacking h2GPI have been produced
by gene targeting; plasma from these knockout
mice exhibited impaired thrombin generation in
vitro. In heterozygous mice, thrombin generation
was not as impaired as in the knockouts. This
suggests a correlation between thrombin genera-
tion and h2GPI levels [26]. These experiments
provide direct evidence of the role of h2GPI in
the direct coagulation cascade, at a stage upstream
of thrombin generation [27]. Nevertheless, the
exact role of h2GPI in the clotting process is not
fully elucidated. The generation of thrombin, for
instance, is important for both thrombus formation
and the initiation of the protein C anticoagulation
pathway. Interestingly, h2GPI-deficient individuals
are apparently not at risk of thrombosis [22], and
most of their haemostatic and fibrinolytic markers
are normal.
The involvement of h2GPI in the coagulation
cascade seems multifaceted because the protein
can exert both procoagulant and anticoagulant
activities. The binding of h2GPI to anionic phos-
pholipids on activated platelets and endothelial
cells (ECs) possibly results in the competition
between h2GPI and coagulation factors for phos-
pholipid surfaces [1]. On the other hand, as
previously mentioned, plasmin and—less effi-
ciently—FXa in vitro can cleave Lys317—Thr318 in
the fifth domain of h2GPI, abolishing its binding to
anionic phospholipids [14]. This phenomenon is
enhanced by heparin [6]. Proteolytically cleaved
h2GPI at Lys
317—Thr318 inhibits plasmin generation
by tissue plasminogen activation (tPA; [28]). The
conversion of plasminogen to plasmin by tPA is a
key event in the fibrinolytic system. As plasmin is a
critical protease in this system, the regulation of
plasmin generation is important in in vivo haemo-
stasis. Cleaved h2GPI is found in the plasma of
patients with lupus anticoagulant, in patients who
have had ischaemic stroke, and in healthy indi-
viduals with a history of lacunar infarcts [28].
Figure 2 The main steps of the intrinsic pathway of the coagulation system and the fibrinolytic mechanism, together
with proposed interferences of h2GPI. Effects promoting clot formation (procoagulant actions) are represented with
continuous arrows, whereas effects inhibiting clot formation or promoting fibrinolysis (anticoagulant actions) are
represented with dotted arrows. Factors of the intrinsic coagulation pathway are shown with plain characters, and
elements of the fibrinolytic mechanism are given in italic characters.
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h2GPI cleaved at Lys
317—Thr318 is also generated in
vivo in pathological states of increased fibrinolysis
[15] and provides an important feedback mecha-
nism between h2GPI and the components of the
coagulation cascade (Fig. 2). Additionally, the
suppression of plasma intrinsic fibrinolytic activity
by h2GPI, reversed by monoclonal anti-h2GPI
antibodies in the presence of h2GPI, has been
described [29]. Hence, h2GPI appears to not only
interact with factors of the coagulation cascade,
but also participate in the regulation of intrinsic
fibrinolysis.
Procoagulant actions of h2GPI also include the
prevention of FVa degradation by activated protein
C [30]. This is potentiated in the presence of
anticardiolipin antibodies. On the other hand,
anticoagulant activities of h2GPI include the
inhibition of the ADP-mediated aggregation of
platelets and the impairment of thrombin gener-
ation by the prothrombinase complex, also ampli-
fied in the presence of aPLAb [30]. It must be
emphasized, however, that the data acquired in
vitro regarding the function of h2GPI needs to be
cautiously interpreted. Whether such findings
represent a true biological effect needs to always
be verified with in vivo experiments.
h2GPI inhibits the activation of FXII in the
presence of negatively charged phospholipids
[31]. This in turn may inhibit the activation of the
intrinsic coagulation pathway. Furthermore, h2GPI
also inhibits the generation of FXa in the presence
of activated platelets. The presence of aPLAb
abolishes this inhibitory effect, resulting in pro-
tracted, unopposed FXa generation [32].
Recently, it has been demonstrated that h2GPI
binds FXI in vitro at concentrations lower than
those of h2GPI in human plasma, and this binding of
h2GPI to FXI inhibits its activation to FXIa by
thrombin and FXIIa [16]. The affinity of the
interaction between h2GPI and FXI is equivalent
to the known classical interaction between FXI and
high molecular weight kininogen (HK). Site-direc-
ted mutagenesis indicates that the binding of h2GPI
to FXI is mediated by the terminal C region of the
fifth domain. The positively charged residue sites
Lys284, Lys286 and Lys287 in this domain of h2GPI are
essential for the h2GPI—FXI interaction (Shi et al.
unpublished data). Furthermore, proteolytic clip-
ping of h2GPI by plasmin at Lys
317—Thr318 of the
fifth domain abolishes h2GPI inhibition of FXI
activation. Cleaved h2GPI retains its ability to bind
FXI [16].
The interaction of h2GPI with FXI has extended
our understanding of the role of h2GPI in the
mechanisms of blood coagulation (Fig. 2). The
activation of FXI by thrombin results in additional
thrombin generation inside the fibrin clot. Throm-
bin formation, in turn, triggers the activation of
thrombin activatable fibrinolysis inhibitor (TAFI),
which protects the fibrin clot against lysis, by
inhibiting the activation of plasminogen to plasmin
[33]. The recent association of TAFI levels with
levels of FXI and high risk of recurrent thrombosis
further emphasizes the importance of this mecha-
nism for blood rheology [34]. On the other hand, it
appears that FXI/FXIa binds to activated human
platelets in vivo in the presence of HK and zinc or
prothrombin and calcium ions [35]. Hence, the
ability of h2GPI to bind FXI suggests that h2GPI may
substitute for HK or prothrombin in vivo in the
interaction of FXI with activated platelets. The
interaction of h2GPI with FXI on the surface of
activated platelets could facilitate not only the
inhibition of FXI activation, but also the subsequent
generation of cleaved h2GPI by plasmin in a clot.
Therefore, the regulation of FXI activation and the
plasmin cleavage of h2GPI in thrombosis may
provide a negative feedback loop in FXI activation
and the subsequent thrombin burst (Fig. 2). It
seems that h2GPI is implicated in both the coagu-
lation and the fibrinolytic pathways, and that,
possibly, one of the main anticoagulant actions of
h2GPI under normal physiologic conditions is the
attenuation of the intrinsic coagulation pathway by
inhibiting FXI activation by thrombin.
B2GPI and atherosclerosis
Immunoreactivity against h2GPI has been detected
in atherosclerotic plaque. The interaction of aPLAb
with the h2GPI/ox-LDL complex has been described
elsewhere in this text. h2GPI can also bind to
lipoprotein (a) [Lp(a)], a molecule conferring a
putative risk for atherosclerotic disease, which
shares high homology to plasminogen [36]. In
comparison, despite great homology between
Lp(a) and plasminogen, it is only the proteolytically
cleaved h2GPI that binds plasminogen and not the
native molecule, highlighting that cleavage of
h2GPI is a critical process in the regulation of the
fibrinolytic pathway.
Taken together, the above data argue for an
interaction between h2GPI and the components of
the atherosclerotic plaque. Antiphospholipid anti-
bodies may interfere with this process. The in vivo
significance of these findings remains unclear
because, in contrast with the protean features of
APS (thrombosis, miscarriage), atherogenesis in
h2GPI knockout mice has not been extensively
studied yet.
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The antiphospholipid syndrome
Antiphospholipid antibody syndrome (APS) is char-
acterised by the occurrence of a constellation of
clinical manifestations associated with the pres-
ence of antiphospholipid antibodies (aPLAb; [13]).
Clinical features of APS mainly include recurrent
venous and arterial thrombosis, thrombocytopenia,
recurrent spontaneous miscarriages, various neuro-
logical syndromes, as well as livedo reticularis [13].
The aPLAb are directed against either anionic
phospholipids or phospholipid-binding protein epit-
opes. The syndrome may occur alone (in which
case, it is referred to as the primary APS) or in
association with systemic lupus erythematosus
(SLE), other autoimmune diseases, and rarely with
infections and drugs (secondary APS; [13]).
The aPLAb can be detected either via the Lupus
Anticoagulant (LA) in vitro coagulation test or via
ELISA assays for antibodies interacting with cardi-
olipin (aCL) and/or h2GPI [13]. h2GPI constitutes
the major antigenic target for aPLAb circulating in
the plasma of APS patients [3]. Although there is no
gold-standard diagnostic test for APS, it is evident
that the h2GPI ELISA has high specificity and
positive predictive value for the diagnosis of APS.
The presence of anti-h2GPI antibodies significantly
correlates with thrombotic manifestations in APS
patients [37,38]. Furthermore, most cases of clin-
ically significant LA are associated with the con-
comitant presence of anti-h2GPI antibodies in the
sera of APS patients [39].
The detection of h2GPI as the major antigenic
target of aPLAb was a breakthrough in the under-
standing of the pathophysiology of the APS [3]. The
increase in affinity of h2GPI for anionic phospholi-
pid upon antibody binding further supports the
pathogenetic role of this molecule in disorders
caused by aPLAb, possibly through interference
with phospholipid-dependent steps in coagulation,
reversible in the presence of excess phospholipid
[40]. The precise role, however, of h2GPI, as well as
the exact mechanism of h2GPI—phospholipid inter-
action in antibody binding, are still unresolved, and
several hypotheses have emerged. In contrast with
the phospholipid binding site, which lies in domain
V of h2GPI, the major immunodominant epitope on
h2GPI is localised on domain I [41].
Platelet activation and B2GPI. The role of
the Apolipoprotein E receptor 2
It must be emphasized that, in contrast to mouse
anti-h2GPI, human autoantibodies against h2GPI
generally show low affinity for binding h2GPI in
standard ELISA assays [13]. Therefore, it has been
hypothesized that antibody binding to h2GPI immo-
bilised on a surface is facilitated by the concen-
tration of the protein on the surface, which brings
about clustering of antigenic sites, allowing the
bivalent binding of otherwise low-affinity anti-
bodies [25,42]. Dimeric h2GPI has been demonstra-
ted to increase platelet adhesion to collagen in an
in vitro system that mimicked the effect on
platelets produced by the in vivo existence of
aPLAb [42]. Because the binding of dimerized
h2GPI to negatively charged phospholipids is not
enough to sensitize platelets, it seems that after
the binding of dimeric h2GPI to the platelet, an
interaction of dimeric h2GPI with a receptor on the
platelet surface is involved in further activation
[42].
Apolipoprotein E receptor 2 (ApoER2), a member
of the LDL receptor family, offers an attractive
possible candidate for binding dimeric h2GPI.
Members of the LDL receptor family have specific
protein modules of extracellular ligand binding
repeats, as well as a cytoplasmic region containing
motifs for endocytosis and signal transduction [43].
A splice variant of ApoER2 is the only member of
the LDL receptor family found on the platelet
membrane. Increased platelet adhesion observed
with dimeric h2GPI disappeared after preincubation
with the receptor-associated protein (RAP), which
is known to inhibit the interaction of ligands with
members of the LDL receptor family [42]. Further-
more, using phage display technology, a peptide
region on ApoER2, which specifically interacts with
h2GPI, has recently been identified (Krilis et al.,
unpublished observations). The coprecipitation of
dimeric h2GPI with ApoER2 suggests that ApoER2
indeed mediates the effects of dimeric h2GPI on
platelets [42].
It is therefore likely that autoantibodies to
h2GPI form complexes with h2GPI able to bind to
activated platelet surface receptors, like ApoER2
(Fig. 3). This binding sensitizes platelets to low
concentrations of thrombin, resulting in adherence
to collagen [1,42]. It has been demonstrated in
this system that dimeric h2GPI constructs and anti-
h2GPI antibodies can induce platelet adhesion,
thrombus formation and thromboxane A2 produc-
tion [42]. Plasmin-mediated cleavage of the
carboxy terminus of domain V, potentiated by
proteoglycans, would induce the dissociation of
the h2GPI—anti-h2GPI complex from ApoER2 (Fig.
3). This model is proposed for platelet activation
and involves a platelet cell surface receptor
(likely ApoER2) interacting with the bivalent
h2GPI—anti-h2GPI aPLAb complexes. However,
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inasmuch as many different cell types express
members of the LDL receptor family on their
surface, this model might also apply to the
activation of other cell types in the APS, possibly
involving receptors for h2GPI other than ApoER2,
in the LDL receptor family.
Recurrent fetal loss in APS. The role of
B2GPI
Recurrent miscarriage is one of the main features
of APS [13]. Evidence for a pathogenetic role of
aPLAb in pregnancy first came when a passive
immunization of pregnant mice with aPLAb from
women with APS led to murine pregnancy loss in
some, but not all, cases [44]. aPLAb reacting with
h2GPI can inhibit the proliferation and secretory
activity of human placental trophoblast cells,
confirming the involvement of h2GPI in pregnancy
loss associated with APS. The presence in the sera
of pregnant women of h2GPI-dependent aPLAb
(compared with h2GPI-independent antibodies)
significantly correlates with adverse pregnancy
outcomes (miscarriage, preeclampsia and retarded
fetal growth), and the detection of anti-h2GPI
aPLAb has the greatest predictive value for preg-
nancy complications, among the conventional diag-
nostic tests for APS [45]. Taken together, these data
argue for h2GPI as the principal antigenic target in
APS-related fetal loss.
The exact role of antibodies against h2GPI in
the miscarriage process in APS is not fully
elucidated yet. One hypothesis suggests that they
prevent implantation in vivo, by the binding of
aPLAb to the trophectoderm of preimplantation
embryos [46]. Another suggested mechanism is
that there is impaired placental prostaglandin
synthesis, due to the interaction of aPLAb with
the h2GPI-mediated activity of lipoprotein lipase
on maternal membrane phospholipids [47]. It has
also been proposed that there is an increased
macrophage uptake of oxidised LDL, secondary to
aPLAb binding, inducing, thus, placental athero-
genesis [20]. The absence of thrombocytopenia
despite fetal loss [48] supports the argument that
platelet consumption in placental thrombotic
events is not the predominant mechanism of
recurrent miscarriages in APS. Interestingly, exist-
ing in vivo data on the influence of either aPLAb
or h2GPI on murine pregnancies are, thus far,
conflicting [27]. It is evident that the sole
existence of aPLAb is not sufficient for explaining
recurrent fetal loss in human APS because such
antibodies are present in only one-tenth of
recurrent aborters, while they are present—but
without clinical significance—in a high proportions
of normal pregnancies [49].
The role of h2GPI in pregnancy failure has been
further elucidated following experiments on genet-
ically modified mice lacking h2GPI [10,26]. h2GPI
knockout mice are able to carry pregnancies to
term, with reproductive outcomes indistinguish-
Figure 3 Autoantibodies to h2GPI circulate in plasma but do not bind h2GPI because of low affinity. Once cell activation
exposes anionic PL (for example, on platelet surface), the dimerisation of h2GPI then facilitates binding to h2GPI cell
surface receptor (ApoER2 for platelet cells) and cell signaling. Plasmin cleavage at the site of thrombus formation
potentiated by proteoglycans cleaves h2GPI carboxy terminus and dissociates binding from its receptor. In the absence of
h2GPI, the autoantibodies cannot induce their pathogenic effects. Reproduced with permission from Miyakis et al. [27].
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able from that of the control mice [26]. h2GPI
deficiency, however, is associated with a 15%
reduction in litter size, compared with heterozy-
gote and wild-type pregnancies, along with subtle
changes in placental size and structure, indicative
of impaired placental efficiency [48]. On the other
hand, when h2GPI heterozygotes on a 129/Sv/
C57BL/6 mixed genetic background were inter-
crossed, only 8.9% of the resulting offspring were
homozygous for the deletion, which is significantly
lower than the expected 1:2:1 Mendelian ratio,
implying that the lack of h2GPI action confers a
selective disadvantage on survival [26]. This is
probably the result of a defect at implantation or
at even earlier reproductive stages (ovulation,
early embryogenesis) because litter sizes were
comparable in heterozygote and wild-type preg-
nancies. Taken together, data from knockout mice
indicate that h2GPI is necessary to achieve the full
effect on fetal loss mediated by aPLAb; however,
the elimination of h2GPI action does not seem to be
the principal pathogenetic mechanism for APS-
related pregnancy loss.
Interestingly, pregnancy in h2GPI-deficient mice
was associated with an increase in mean blood
platelet count of 35%, rather than thrombocyto-
penia, which characterizes APS [26]. Moreover,
passive immunization with aPLAb in pregnant
h2GPI null mice resulted in an increased blood
platelet content late in gestation, compared with
virgin animals or animals during early pregnancy
[48]. On the other hand, passive antibody transfer
experiments also showed that some antibody
preparations elicited more severe pregnancy path-
ologies in the presence of endogenous h2GPI than
in h2GPI null mutant animals [48]. The synthesis of
the above data to coherently explain the possible
pathogenic mechanisms operating in patients with
the APS may initially seem difficult. An attractive
hypothesis is that aPLAbs may play a pathogenic
role by potentiating, rather than abolishing, at
least some of the effects of h2GPI. In this scenario,
the procoagulant actions of h2GPI would be
amplified in the presence of aPLAbs, thus explain-
ing the prothrombotic tendency seen in patients
with APS.
The role of B2GPI in the thrombotic
events of APS
Recurrent thrombosis affecting arteries, veins or
both is a cardinal clinical feature of APS [13]. The
direct anti-h2GPI ELISA has high specificity (0.88—
0.99) for thrombosis. aPLAb against h2GPI show the
highest predictive value among aPLAb, especially
for arterial thrombosis in APS [50]. Given the
multiple interactions of h2GPI with factors of both
the coagulation and fibrinolysis pathways (exten-
sively discussed elsewhere in this text), aPLAb are
expected to be involved in the pathogenesis of
thrombotic events that characterise APS. Interfer-
ence of the normal physiological interaction
between h2GPI and the coagulation factors by
aPLAb constitutes a possible pathogenic mechanism
for APS-related thrombosis. The inhibition of FXa
generation on activated platelets by h2GPI has
been shown to be counteracted by aPLAb, leading
to an increased, unopposed FXa generation [32]. An
alternative explanation for APS-related thrombosis
is that aPLAb showing generally low-antigen affin-
ity may efficiently bind platelet-associated h2GPI,
thereby blocking its attenuating effect on FXI
activation. The cleavage of h2GPI by plasmin
provides a negative feedback to FXI activation
and the subsequent thrombin burst. The cleavage
of h2GPI at Lys
317—Thr318 has been demonstrated in
patients with LA, independent of plasmin activa-
tion, implying that aPLAb may also have an effect
on h2GPI cleavage [51].
Another mechanism by which aPLAb directed
against h2GPI may predispose an individual with
APS to thrombosis is by interfering with the
fibrinolytic mechanism. The proteolytic degrada-
tion of both FVa and FVIIIa is mediated by the
protein S-activated protein C (APC) complex, and
the activation of protein C is greatly enhanced by
phospholipids [52]. Both rabbit and human mono-
clonal aPLAb can inhibit FVa degradation, the
effect being h2GPI dependent [30]. Moreover, in
an in vitro system, the LA effect on thrombin
generation (and on the subsequent degradation of
FVa) was dependent on affinity-purified anti-
h2GPI—but not on antiprothrombin—antibodies
[53]. Thus, it can be proposed that the underlying
mechanism for the inhibition of the APC complex
by anti-h2GPI/aPLAb is via competition for
anionic phospholipid binding sites (Fig. 2). On
the other hand, the recently described interac-
tion between h2GPI and FXI provides an attractive
alternative mechanism for the involvement of
h2GPI in the pathogenesis of APS via interference
with the fibrinolytic system: h2GPI cleavage by
plasmin abolishes h2GPI inhibition of FXI activa-
tion. This results in excessive activation of the
coagulation pathway and thrombin formation.
Thrombin, in turn, inhibits plasmin production
by plasminogen (via TAFI; Fig. 2). Therefore,
cleaved h2GPI inhibits the activation of plasmi-
nogen to plasmin, thus further attenuating the
fibrinolytic system.
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Nevertheless, a lot of unresolved issues remain
regarding the interaction of h2GPI with elements of
the fibrinolytic system. For instance, the APC
complex mediates both procoagulant and antico-
agulant effects in h2GPI-depleted plasma in vitro.
The clinical significance of this observation remains
uncertain [30]. On the other hand, disorders arising
from hereditary deficiencies of the fibrinolytic
system proteins typically only entail venous throm-
bosis and are rarely associated with arterial events
or miscarriage. Furthermore, apart from anti-
h2GPI/aPLAbs, antibodies against prothrombin,
protein C, protein S and annexin V have been
detected in patients with SLE-associated APS.
These antibodies confer independent, significant
risk factors for thrombosis and fetal loss [54]. Taken
together, the above data make the association
between h2GPI and the fibrinolytic system more
complicated and difficult to fully interpret as an
isolated mechanism contributing to thrombotic
events of APS patients.
The effect of aPLAb in the pathogenesis of APS-
associated thrombosis may also be considered in
relation to protein Z (PZ). PZ is a vitamin-K-
dependent plasma protein that serves as a cofac-
tor for the inactivation of FXa by protein-Z-
dependent protease inhibitor (ZPI). Evidence
exists that PZ plays an important role in coagu-
lation regulation because of the PZ-dependent
inactivation of FXa by ZPI. Recently, it has been
demonstrated that FXa inhibition by PZ/ZPI is
attenuated, to some extent, by h2GPI [55]. Most
isolated aPLAb were found to further enhance the
inhibitory potential of h2GPI on PZ/ZPI activity.
Without h2GPI, the PZ/ZPI activity was unaffected
by the addition of isolated aPLAb. Because the
generation of thrombin is closely related to the
concentration of FXa, the sum of these aPLAb
effects could be inappropriate thrombin genera-
tion and an increased risk for thrombosis, possibly
via the potentiation of the h2GPI action on FXa
inactivation by PZ/ZPI [55]. The high prevalence
of PZ deficiency in association with aPLAb has
been detected, as well as significantly lower PZ
levels in a definite APS group of patients, but not
in the non-APS group, compared with the normal
group [55].
Finally, aPLAb against h2GPI have been shown
to exert direct antiendothelial cell activity in APS
patients [56]. The binding of aPLAb to h2GPI on
the endothelial cell (EC) surface—mediated
through the specific cell surface receptor annexin
II—results in EC activation via the up-regulation of
adhesion molecules and cytokines. This induces a
proinflammatory and procoagulant phenotype in
endothelial cells [56]. This effect also implies
that aPLAb, in the presence of h2GPI, may well
bind to healthy ECs without anionic phospholipid
involvement.
An alternate hypothesis is that anti-h2GPI anti-
bodies activate ECs through the MyD88-dependent
signaling pathway, via involvement of the toll-like
receptors (TLR) family [57]. Because TRLs form
functional signaling pairs (homodimers or hetero-
dimers) on interaction with the proper ligand, it
has been suggested that anti-h2GPI antibodies
might cross link h2GPI molecules together with
TLRs, eventually favoring the receptor polymer-
ization and the signaling cascade [57]. h2GPI shares
amino acid sequence in common with different
microbial pathogens [58], further supporting an
association between h2GPI and TLRs. This recent
hypothesis seems very interesting, given also the
increase of aPLAb transiently observed during
infections [13], the frequent occurrence of APS-
related events in patients with chronic viral
infections [59] and, perhaps more importantly,
the clinical association between the so-called
catastrophic variant of APS and infections as
triggering events [60].
Summary and perspectives
h2GPI is one of the most abundant plasma proteins,
and this fact implies a significant role in human
physiology. Indeed, the structure of h2GPI confers
to the protein the ability to bind phospholipids, as
well as to interact with a wide range of other
proteins. Evidence thus far indicates that h2GPI (a)
interacts with steps in the coagulation and fibrino-
lytic pathways, (b) is necessary for placental
homeostasis and for optimal implantation, and (c)
may be involved in other processes, such as
atheromatous plaque formation, endothelial cell
activation and the apoptotic mechanism. A more
detailed review on apoptosis and antiphospholipid
antibodies is published in this volume of Thrombosis
Research, by Rauch et al.
h2GPI constitutes the main antigenic target of
autoantibodies in the APS. It has been proposed
that aPL acquire pathogenicity in APS upon the
abolishment of at least some of the physiological
actions of h2GPI. The recently demonstrated
inhibition of FXI activation [16] gives a character-
istic model with multiple interactions and feed-
back mechanisms, in which h2GPI holds a key role.
h2GPI may attenuate thrombin generation in vivo
by inhibition of FXI activation. Plasmin cleavage of
h2GPI provides a negative feedback that counter-
acts its inhibition of FXI activation. Important
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questions, however, have not yet been answered.
(1) Although h2GPI binds FXI via its fifth domain,
the exact mechanism that leads to inhibition of
FXI activation is not known. It is likely that the
binding of h2GPI to FXI causes a conformational
change such that FXI does not bind to anionic
phospholipids or the proteases thrombin and FXIIa.
This hypothesis needs to be proved. (2) What is
the exact nature of the interference of aPLAb with
the h2GPI actions? Although it was classically
believed that antibodies abolish h2GPI effect,
recent data suggest that—at least in some
cases—the enhancement of h2GPI activation by
the autoantibodies in vivo is a more likely
possibility. This apparent inconsistency between
in vitro and in vivo data must be examined in light
of the fact that h2GPI in vivo may bind surface
receptors, such as ApoER2, annexin II and proteo-
glycans, on surfaces of cells, in addition to
negatively charged phospholipids.
Not surprisingly, thus, in vitro data so far
suggests that h2GPI exerts multiple actions, some
of them procoagulant and some anticoagulant.
Which of these actions are of clinical importance
and how exactly their balance is disrupted in the
APS remains to be examined in vivo. It has been
hypothesized that, despite multiple in vitro inter-
actions of h2GPI with the coagulation and fibrino-
lytic pathways, exerting both procoagulant and
anticoagulant functions, the net in vivo effect of
h2GPI must be anticoagulant. The neutralization of
this effect by anti-h2GPI aPLAb confers the pro-
thrombotic status that characterizes APS. Even if
such simplicity is to be accepted, a net anti-
coagulant in vivo effect for h2GPI has not been
demonstrated thus far. This could mean that (1)
such a simplified explanation for the role of h2GPI is
not valid, (2) h2GPI is not pathogenic for APS, and/
or (3) the protein exerts a net procoagulant in vivo
effect. If the latter were correct, then related
antibodies must act synergistically, enhancing the
h2GPI effect in APS, and evidence towards this
hypothesis has been provided from recent data. An
alternative hypothesis is that anti-h2GPI aPLAb
indeed neutralize such a procoagulant action of
h2GPI, initially conferring an inappropriate anti-
coagulant subclinical phenotype in APS. The main-
tenance of such a phenotype would promote the
consumption of elements of the coagulation cas-
cade, as well as the exhaustion of fibrinolytic
factors, so that thrombotic episodes eventually
manifest in the vasculature of sites so predisposed
for anatomical reasons. The latter hypothesis can
be supported by the fact that thrombosis tends to
recur at the same part of the vasculature (arterial
vs. venous) in a given APS patient. In any case, it is
likely that the net effect of the assumed opposing
h2GPI actions would depend on the microenviron-
ment at a particular stage.
Experiments performed so far in h2GPI knockout
mice have suggested a role for h2GPI in embryonic
implantation and the optimal functioning of the
placenta [48]. Important and still unsettled ques-
tions arise regarding the exact stage of early
pregnancy that is compromised in the absence of
h2GPI. Hence, the exact function of h2GPI, even in
the undisputed areas of its involvement in APS (that
is, recurrent thrombosis and miscarriage), remains
to be elucidated. The proposed model for platelet
activation upon the interaction of the bivalent
h2GPI-antibody complexes with the platelet recep-
tor ApoER2 could also apply to the activation of
other cell types in the APS. The possibility also
exists that the h2GPI—autoantibodies interaction
confers the predisposing background conditions for
APS, and that the clinical manifestations are
triggered by another critical event. Despite the
existence of data supporting this, the validity of
this hypothesis, as well as the exact candidate
triggering event (infection, surgery, pregnancy,
long immobilisation, etc.), needs to be further
explored.
Another important issue that needs to be
elucidated is the precise role of h2GPI in athero-
genesis and its possible clinical implications for
APS. Interesting data may emerge from the exami-
nation of the in vivo atherogenic potential of
mammals deprived of h2GPI, as well as their
behaviour under different dietary conditions.
Recently, the promoter of the human h2GPI gene
has been cloned and characterized [8]. This is a
step towards the identification of the genetic
parameters determining h2GPI tissue expression
and its association with other molecules and
relevant interacting genes. These findings, coupled
with the new data on the direct interaction
between h2GPI, FXI and plasmin in the coagulation
and fibrinolysis cascades, have given impetus to the
ongoing research directed towards the illumination
of the role of h2GPI in normal health and in the
pathogenesis of APS.
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